CE-326597 | 870615-40-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: CE-326597
• 英文别名: N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide；PF-00990631；6H-(1,2,4)Triazolo(4,3-a)(1,5)benzodiazepine-6-acetamide, 4,5-dihydro-4-(1H-indol-3-ylmethyl)-N-(1-methylethyl)-5-oxo-1-phenyl-N-(phenylmethyl)-, (S)-；N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4H-[1,2,4]triazolo[3,4-d][1,5]benzodiazepin-6-yl]-N-propan-2-ylacetamide
• CAS: 870615-40-0
• 化学式: C₃₇H₃₄N₆O₂
• 分子量: 594.716
• InChiKey: UBNMGTSDHSQBEL-PMERELPUSA-N

物化性质

• 沸点：
  893.8±75.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  45
• 可旋转键数：
  8
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  87.1
• 氢给体数：
  1
• 氢受体数：
  4

制备方法与用途

这是一种强效且选择性的CCK1受体激动剂，在人和大鼠中的Ki值为36纳摩尔。

反应信息

• 作为反应物：
  描述：

  CE-326597 以 乙醇 为溶剂， 反应 96.0h， 生成 N-benzyl-2-[(4R)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide
  参考文献：
  名称：

  Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity

  摘要：

  We describe the design, synthesis, and structure-activity relationships of triazolobenzodiazepinone CCK1 receptor agonists. Analogs in this series demonstrate potent agonist activity as measured by in vitro and in vivo assays for CCK1 agonism. Our efforts resulted in the identification of compound 4a which significantly reduced food intake with minimal systemic exposure in rodents. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.115
• 作为产物：
  描述：

  N-benzyl-2-{(4S)-4-[(5-bromo-1H-indol-3-yl)methyl]-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl}-N-isopropylacetamide 在 palladium 10% on activated carbon 、 氢气 、 甲酸铵 作用下， 以 甲醇 为溶剂， 以26 mg的产率得到CE-326597
  参考文献：
  名称：

  Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity

  摘要：

  We describe the design, synthesis, and structure-activity relationships of triazolobenzodiazepinone CCK1 receptor agonists. Analogs in this series demonstrate potent agonist activity as measured by in vitro and in vivo assays for CCK1 agonism. Our efforts resulted in the identification of compound 4a which significantly reduced food intake with minimal systemic exposure in rodents. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.115

文献信息

• Bioorganic Medicinal Chemistry Letters 2010, 20, 6797-6801
  作者：

  DOI：——

  日期：——
• Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity
  作者：Richard L. Elliott、Kimberly O. Cameron、Janice E. Chin、Jeremy A. Bartlett、Elena E. Beretta、Yue Chen、Paul Da Silva Jardine、Jeffrey S. Dubins、Melissa L. Gillaspy、Diane M. Hargrove、Amit S. Kalgutkar、Janet A. LaFlamme、Mary E. Lame、Kelly A. Martin、Tristan S. Maurer、Nancy A. Nardone、Robert M. Oliver、Dennis O. Scott、Dexue Sun、Andrew G. Swick、Catherine E. Trebino、Yingxin Zhang

  DOI：10.1016/j.bmcl.2010.08.115

  日期：2010.11

  We describe the design, synthesis, and structure-activity relationships of triazolobenzodiazepinone CCK1 receptor agonists. Analogs in this series demonstrate potent agonist activity as measured by in vitro and in vivo assays for CCK1 agonism. Our efforts resulted in the identification of compound 4a which significantly reduced food intake with minimal systemic exposure in rodents. (C) 2010 Elsevier Ltd. All rights reserved.